BLCM - Bellicum Pharmaceuticals Inc Stock Price, Fair Value and News

0.07USD Market Closed

Market Summary

USD0.07

Market Closed

BLCM Stock Price

View Fullscreen

BLCM RSI Chart

BLCM Valuation

Market Cap

680.2K

Price/Earnings (Trailing)

-0.03

Price/Sales (Trailing)

0.58

Price/Free Cashflow

-0.03

BLCM Price/Sales (Trailing)

BLCM Profitability

Return on Equity

-3.93%

Return on Assets

-326.51%

Free Cashflow Yield

-3.4K%

BLCM Fundamentals

BLCM Revenue

Revenue (TTM)

1.5M

Rev. Growth (Qtr)

20%

BLCM Earnings

Earnings (TTM)

-22.4M

Earnings Growth (Yr)

89.42%

Earnings Growth (Qtr)

89.62%

Breaking Down BLCM Revenue

Last 7 days

14.3%

Last 90 days

-71.4%

Trailing 12 Months

-91.1%

How does BLCM drawdown profile look like?

BLCM Financial Health

Current Ratio

1.82

BLCM Investor Care

Shares Dilution (1Y)

12.81%

Diluted EPS (TTM)

-0.72

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	5.0M	3.9M	2.7M	1.5M
2021	13.7M	11.2M	8.7M	6.2M
2020	18.7M	0	0	16.2M
2019	1.5M	2.5M	2.3M	7.1M
2018	1.0M	1.1M	1.1M	1.1M
2017	738.0K	809.0K	869.0K	1.1M
2016	402.0K	554.0K	721.0K	768.0K
2015	1.3M	865.5K	262.5K	282.0K
2014	1.9M	1.9M	1.8M	1.8M
2013	0	0	0	1.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Bellicum Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 22, 2023	baker bros. advisors lp	acquired	211	0.0001	2,116,350	-
Jan 03, 2023	stonehouse jon p	acquired	-	-	121,452	-
Jan 03, 2023	davis stephen	acquired	-	-	74,739	-
Jan 03, 2023	klimovsky judith v	acquired	-	-	60,414	-
Jan 03, 2023	daly james m	acquired	-	-	60,414	-
Jan 03, 2023	huber reid m	acquired	-	-	80,968	-
Jan 03, 2023	huber reid m	acquired	-	-	87,196	-
Sep 01, 2022	stonehouse jon p	acquired	-	-	60,580	-
Sep 01, 2022	klimovsky judith v	acquired	-	-	35,082	-
Sep 01, 2022	huber reid m	acquired	-	-	46,489	-

Which funds bought or sold BLCM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	WETZEL INVESTMENT ADVISORS, INC.	sold off	-100	-	-	-%
Aug 10, 2023	Tekla Capital Management LLC	unchanged	-	240	2,220	-%
Mar 17, 2023	American Portfolios Advisors	unchanged	-	-	12.00	-%

Are Funds Buying or Selling BLCM?

Are funds buying BLCM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BLCM

No. of Funds

Unveiling Bellicum Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ikarian capital, llc	4.6%	448,101	SC 13G/A
Feb 14, 2024	armistice capital, llc	9.99%	1,078,459	SC 13G/A
Nov 24, 2023	baker bros. advisors lp	19.99%	2,365,472	SC 13D/A
May 05, 2023	baker bros. advisors lp	19.99%	2,197,919	SC 13D
Feb 14, 2023	ikarian capital, llc	5.2%	448,101	SC 13G/A
Feb 14, 2023	armistice capital, llc	9.99%	955,995	SC 13G/A
Feb 09, 2023	vanguard group inc	2.11%	181,843	SC 13G/A
Nov 18, 2022	bellicum pharmaceuticals, inc	7.4%	691,639	SC 13D
Feb 15, 2022	armistice capital, llc	9.99%	932,052	SC 13G/A
Feb 14, 2022	ikarian capital, llc	5.9%	496,756	SC 13G/A

Recent SEC filings of Bellicum Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Mar 01, 2024	15-12G	15-12G
Feb 26, 2024	EFFECT	EFFECT
Feb 26, 2024	EFFECT	EFFECT
Feb 26, 2024	EFFECT	EFFECT
Feb 26, 2024	EFFECT	EFFECT
Feb 26, 2024	EFFECT	EFFECT
Feb 26, 2024	EFFECT	EFFECT
Feb 23, 2024	S-8 POS	Employee Benefits Plan
Feb 23, 2024	8-K	Current Report
Feb 23, 2024	POS AM	POS AM

Peers (Alternatives to Bellicum Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

Bellicum Pharmaceuticals Inc News

Latest updates

Bellicum Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1
Revenue	20.0%	1,000	833	667	500	1,000	833	667	500	5,000	700	4,495	8,289	12,084	5,133	103	1,391	516	312	292	362	154
Operating Expenses	-74.9%	1,774	7,067	8,653	7,840	8,165	6,537	5,939	5,600	8,029	8,487	8,472	12,142	14,619	19,033	23,540	27,550	24,384	26,879	23,520	23,929	22,258
S&GA Expenses	-33.1%	1,511	2,259	1,437	1,501	1,315	1,448	1,453	1,552	1,681	1,765	2,012	3,436	4,171	5,709	9,209	7,518	7,536	6,971	6,968	5,367	5,692
R&D Expenses	-94.5%	263	4,808	7,216	6,339	6,850	5,089	4,486	4,048	6,348	6,722	6,460	8,706	10,448	13,324	14,331	20,032	16,848	20,227	16,413	18,412	16,536
Interest Expenses	-	-	-	-	-	-	-	-	-500*	-	1.00	4.00	186	985	1,043	1,079	1,088	1,070	1,086	1,065	1,045	1,003
Net Income	89.6%	-763	-7,352	-8,066	-6,194	-7,213	-4,003	-7,565	2,531	1,233	-2,202	-11,267	18,814	17,563	-28,981	-32,032	-26,977	-24,449	-27,220	-23,801	-24,175	-22,840
Net Income Margin	22.4%	-14.92*	-19.22*	-16.98*	-16.65*	-6.07*	-2.03*	-1.19*	-1.57*	0.82*	0.46*	-3.16*	-0.58*	-	-	-	-	-	-	-	-	-
Free Cashflow	81.0%	-1,516	-7,992	-6,435	-6,918	-5,905	-6,597	-6,384	-6,028	-1,003	-7,789	-8,293	-13,193	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	-21.5%	7.00	9.00	17.00	24.00	31.00	37.00	43.00	49.00	22.00	24.00	32.00	41.00	60.00	72.00	98.00	116	134	90.00	108	122	144
Current Assets	-21.4%	7.00	9.00	17.00	24.00	31.00	37.00	43.00	49.00	22.00	24.00	31.00	39.00	54.00	68.00	94.00	112	105	59.00	77.00	95.00	116
Cash Equivalents	-20.1%	6.00	7.00	15.00	22.00	29.00	35.00	40.00	48.00	21.00	22.00	41.00	37.00	55.00	68.00	75.00	94.00	103	47.00	47.00	49.00	59.00
Net PPE	-76.2%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.00	2.00	2.00	3.00	16.00	18.00	19.00	21.00	22.00
Liabilities	-35.4%	2.00	3.00	5.00	4.00	6.00	5.00	8.00	7.00	17.00	20.00	26.00	25.00	87.00	100	83.00	121	111	59.00	57.00	53.00	52.00
Current Liabilities	-	-	-	-	4.00	-	-	-	7.00	17.00	20.00	26.00	25.00	69.00	79.00	59.00	94.00	76.00	22.00	16.00	16.00	14.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	18.00	21.00	24.00	26.00	28.00	31.00	36.00	36.00	36.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	10.00	6.00	11.00	11.00	8.00	5.00	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	18.00	21.00	24.00	26.00	-	-	-	36.00	-
Shareholder's Equity	-	-	-	-	2.00	7.00	14.00	17.00	24.00	-	-	-	-	-	-	-	-	1.00	30.00	51.00	68.00	92.00
Retained Earnings	-0.1%	-591	-590	-583	-575	-569	-562	-558	-550	-552	-554	-552	-540	-559	-558	-515	-533	-504	-472	-445	-420	-393
Additional Paid-In Capital	-0.8%	570	574	579	583	582	581	581	580	546	545	544	544	517	515	514	512	510	507	501	494	490
Shares Outstanding	2.3%	10.00	9.00	9.00	9.00	31.00	31.00	31.00	8.00	10.00	10.00	10.00	8.00	5.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	9.00	-	-	-	27.00	-	-	-	32.00	-	-	-	68.00	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	81.0%	-1,516	-7,993	-6,430	-6,911	-5,905	-6,590	-6,377	-6,028	-996	-7,789	-8,293	-13,375	-12,806	-14,214	-16,255	-12,734	-18,788	-21,491	-24,556	-20,401	-16,680
Share Based Compensation	96.6%	116	59.00	559	714	685	611	599	862	853	821	903	538	1,606	1,564	1,323	1,576	1,630	1,996	2,136	2,970	3,676
Cashflow From Investing	1400.0%	15.00	1.00	-5.00	-7.00	-	-7.00	-7.00	-	-7.00	-	900	-22.00	-578	14,717	-37.00	4,182	9,547	17,096	18,032	10,133	-4,021
Cashflow From Financing	-	-	-	-	-	-	-	-	32,908	-	-15.00	-20.00	-4,247	-21.00	-7,953	-2,017	-199	65,177	4,423	4,687	372	3.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BLCM Income Statement

2023-09-30

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues
Revenues	$ 1,000,000	$ 1,000,000	$ 1,008,000	$ 1,000,000
Operating expenses
Research and development	263,000	6,850,000	12,286,000	16,425,000
General and administrative	1,511,000	1,315,000	5,208,000	4,216,000
Total operating expenses	1,774,000	8,165,000	17,494,000	20,641,000
Other operating expense (income)
Gain on disposal of fixed assets, net	(1,000)	0	(1,000)	0
Total other operating income	(1,000)	0	(1,000)	0
Loss from operations	(773,000)	(7,165,000)	(16,485,000)	(19,641,000)
Other income (expense):
Interest income	2,000	11,000	10,000	38,000
Change in fair value of warrant derivative liability	5,000	(59,000)	291,000	827,000
Other income	3,000	0	3,000	0
Total other income (expense)	10,000	(48,000)	304,000	865,000
Net loss	(763,000)	(7,213,000)	(16,181,000)	(18,776,000)
Net loss attributable to common stockholders	(763,000)	(7,213,000)	(16,181,000)	(18,776,000)
Net loss attributable to common stockholders	$ (763,000)	$ (7,213,000)	$ (16,181,000)	$ (18,776,000)
Net loss per common share attributable to common stockholders, basic (in dollars per share)	$ (0.02)	$ (0.23)	$ (0.52)	$ (0.61)
Net loss per common share attributable to common stockholders, diluted (in dollars per share)	$ (0.02)	$ (0.23)	$ (0.52)	$ (0.61)
Weighted-average shares outstanding, basic (in shares)	30,904,808	30,831,161	30,858,466	30,826,683
Weighted-average shares outstanding, diluted (in shares)	30,904,808	30,831,161	30,858,466	30,826,683
Net loss	$ (763,000)	$ (7,213,000)	$ (16,181,000)	$ (18,776,000)
Other comprehensive loss:
Foreign currency translation adjustment	0	(10,000)	0	(15,000)
Comprehensive loss	(763,000)	(7,223,000)	(16,181,000)	(18,791,000)
Supply agreement
Revenues
Revenues	0	0	8,000	0
License revenue
Revenues
Revenues	$ 1,000,000	$ 1,000,000	$ 1,000,000	$ 1,000,000

BLCM Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 5,909	$ 21,837
Accounts receivable, interest and other receivables	15	0
Prepaid expenses and other current assets	924	1,964
Total current assets	6,848	23,801
Property and equipment, net	5	22
Total assets	6,853	23,823
Current liabilities:
Accounts payable	526	486
Accrued expenses and other current liabilities	1,205	2,477
Warrant derivative liability	518	809
Total liabilities	2,249	3,772
Commitments and contingencies
Redeemable preferred stock: $0.01 par value; 10,000,000 shares authorized. Series 1 redeemable convertible preferred stock, $0.01 par value; 1,517,500 shares authorized at September 30, 2023 and December 31, 2022; 452,000 shares issued and outstanding at September 30, 2023 and December 31, 2022	31,618	18,036
Stockholders’ (deficit) equity:
Common stock, $0.01 par value; 160,000,000 shares authorized at September 30, 2023 and December 31, 2022; 9,784,677 shares issued and 9,716,931 shares outstanding at September 30, 2023; 8,682,447 shares issued and 8,614,701 shares outstanding at December 31, 2022	98	87
Treasury stock: 67,746 shares held at September 30, 2023 and December 31, 2022	(5,056)	(5,056)
Additional paid-in capital	569,904	582,763
Accumulated other comprehensive loss	(354)	(354)
Accumulated deficit	(591,606)	(575,425)
Total stockholders’ (deficit) equity	(27,014)	2,015
Total liabilities, redeemable preferred stock and stockholders’ equity	$ 6,853	$ 23,823

About Bellicum Pharmaceuticals Inc

Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.

WEBSITE	bellicum.com
INDUSTRY	Biotechnology
EMPLOYEES	13

Bellicum Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Bellicum Pharmaceuticals Inc? What does BLCM stand for in stocks?

BLCM is the stock ticker symbol of Bellicum Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bellicum Pharmaceuticals Inc (BLCM)?

As of Mon Mar 04 2024, market cap of Bellicum Pharmaceuticals Inc is 680.18 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BLCM stock?

You can check BLCM's fair value in chart for subscribers.

What is the fair value of BLCM stock?

You can check BLCM's fair value in chart for subscribers. The fair value of Bellicum Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bellicum Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BLCM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bellicum Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether BLCM is over valued or under valued. Whether Bellicum Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Bellicum Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BLCM.

What is Bellicum Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Mar 04 2024, BLCM's PE ratio (Price to Earnings) is -0.03 and Price to Sales (PS) ratio is 0.58. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BLCM PE ratio will change depending on the future growth rate expectations of investors.